Hikma Pharmaceuticals received buy ratings and increased price targets from Citigroup and Deutsche Bank following stronger-than-expected half-year financial results. The company's core operating profit rose 8.6% to $405 million, beating market expectations by 11%, while adjusted earnings per share exceeded forecasts by 14%. The positive outlook is driven by growth in injectables and branded medicines, especially in the Middle East and North Africa. Analysts have raised revenue forecasts for 2026 to 2030, signaling confidence in Hikma's future performance.
Genius Group, after selling its entire Bitcoin reserve to repay $8.5 million in debt, plans to rebuild its Bitcoin and AI treasuries to a combined $1.6 billion by fiscal year 2031. The company aims to grow total assets to $2 billion and will fund tre...
Veteran trader Peter Brandt revealed he remains long on Bitcoin even as the cryptocurrency struggles to break above the key resistance zone around $82,000. Bitcoin recently climbed above $80,000 but faced strong selling pressure, causing a pullback. ...
Grayscale's Zach Pandl highlights that the US Treasury's bond repurchases aim to ease pressure from soaring government debt, which recently surpassed $40 trillion. While these repurchases may reduce Treasury supply and stimulate the economy, they don...
GoMining introduced Instant Funds, a feature enabling eligible digital Bitcoin miner NFT holders to use their miners as collateral to borrow stablecoins like USDT or USDC without selling the miners. Users can access up to 30% of the miner's value wit...
World Liberty Financial's proposed US trust bank has secured a significant investment from Sheikh Tahnoon bin Zayed Al Nahyan's group, which controls 49% of the holding company behind the bank. Another 38% is reportedly owned by an entity affiliated ...
